Zonghai Li, CARsgen founder, CEO and CSO
August 21, 2023 07:17 AM EDTUpdated 10:29 AM
Deals

Mod­er­na and CARs­gen team up on CAR-T cell ther­a­py and mR­NA can­cer vac­cine com­bo

Katherine Lewin

News Reporter

CARs­gen will test its Claudin18.2 CAR T-cell can­di­date, dubbed CT041, in com­bi­na­tion with Mod­er­na’s in­ves­ti­ga­tion­al mR­NA can­cer vac­cine in a col­lab­o­ra­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times